Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

365 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety.
Heldmann F, Baraliakos X, Kiltz U, Brandt J, van der Horst-Bruinsma IE, Landewé R, Sieper J, Burmester GR, van den Bosch F, de Vlam K, Gaston H, Gruenke M, Witt M, Appelboom T, Emery P, Dougados M, Leirisalo-Repo M, Breban M, Braun J. Heldmann F, et al. Among authors: van der horst bruinsma ie, van den bosch f. Clin Exp Rheumatol. 2016 Mar-Apr;34(2):184-90. Epub 2016 Mar 25. Clin Exp Rheumatol. 2016. PMID: 27049733
A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.
Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gömör B, Van Den Bosch F, Nordström D, Bjorneboe O, Dahl R, Horslev-Petersen K, Rodriguez De La Serna A, Molloy M, Tikly M, Oed C, Rosenburg R, Loew-Friedrich I. Emery P, et al. Among authors: van den bosch f. Rheumatology (Oxford). 2000 Jun;39(6):655-65. doi: 10.1093/rheumatology/39.6.655. Rheumatology (Oxford). 2000. PMID: 10888712 Clinical Trial.
Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?
Baeten D, Kruithof E, Van den Bosch F, Van den Bossche N, Herssens A, Mielants H, De Keyser F, Veys EM. Baeten D, et al. Among authors: van den bosch f, van den bossche n. Ann Rheum Dis. 2003 Sep;62(9):829-34. doi: 10.1136/ard.62.9.829. Ann Rheum Dis. 2003. PMID: 12922954 Free PMC article.
A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study.
Durez P, Van den Bosch F, Corluy L, Veys EM, De Clerck L, Peretz A, Malaise M, Devogelaer JP, Vastesaeger N, Geldhof A, Westhovens R. Durez P, et al. Among authors: van den bosch f. Rheumatology (Oxford). 2005 Apr;44(4):465-8. doi: 10.1093/rheumatology/keh494. Epub 2005 Feb 3. Rheumatology (Oxford). 2005. PMID: 15695306
Anti-TNF-alpha therapy in ankylosing spondylitis.
De Keyser F, Van den Bosch F, Mielants H. De Keyser F, et al. Among authors: van den bosch f. Cytokine. 2006 Mar 7;33(5):294-8. doi: 10.1016/j.cyto.2006.01.004. Epub 2006 Mar 3. Cytokine. 2006. PMID: 16516484 Review.
365 results